Esperion Therapeutics (ESPR) News Today $2.41 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Buy Rating Affirmed for Esperion Due to Bempedoic Acid’s Clinical Efficacy in Recent TrialsNovember 20 at 8:04 AM | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday.November 19 at 8:22 AM | marketbeat.comEsperion highlights exploratory data from CLEAR outcomes trial of NexletolNovember 19 at 3:57 AM | markets.businessinsider.comEsperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024November 18 at 10:30 AM | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Lowered to Hold Rating by StockNews.comNovember 17, 2024 | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Cut to "Hold" at StockNews.comStockNews.com lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday.November 15, 2024 | marketbeat.comEsperion Therapeutics: Growth Initiatives Are Paying Off - BuyNovember 13, 2024 | seekingalpha.comWhat is HC Wainwright's Forecast for ESPR FY2025 Earnings?November 12, 2024 | americanbankingnews.comHC Wainwright Has Positive Estimate for ESPR FY2025 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the biopharmaNovember 11, 2024 | marketbeat.comStockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Buy"November 11, 2024 | americanbankingnews.comEsperion Therapeutics Sees Significant Revenue Growth in Q3 2024November 9, 2024 | markets.businessinsider.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)November 8, 2024 | globenewswire.comEsperion Therapeutics' (ESPR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Friday.November 8, 2024 | marketbeat.comEsperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...November 8, 2024 | finance.yahoo.comEsperion Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 7, 2024 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Rating Increased to Buy at StockNews.comStockNews.com upgraded shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday.November 7, 2024 | marketbeat.comEsperion to Participate in Upcoming Jefferies London Healthcare ConferenceNovember 4, 2024 | globenewswire.comEsperion Therapeutics (ESPR) to Release Quarterly Earnings on ThursdayEsperion Therapeutics (NASDAQ:ESPR) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639690)October 31, 2024 | marketbeat.comBank of America Securities Keeps Their Sell Rating on Esperion (ESPR)October 28, 2024 | markets.businessinsider.comStockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to BuyStockNews.com upgraded shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday.October 26, 2024 | marketbeat.comEsperion to Report Third Quarter 2024 Financial Results on November 7October 24, 2024 | globenewswire.comMillennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc HoldingsOctober 17, 2024 | finance.yahoo.comEsperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.comStockNews.com raised shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday.October 15, 2024 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q1 2025 Earnings of ($0.16) Per Share, Zacks Research ForecastsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Tuesday, October 8th. Zacks Research analyst K. Das now anticipates that the biophOctober 11, 2024 | marketbeat.comZacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research lowered their FY2025 earnings per share estimates for shares of Esperion Therapeutics in a research report issued to clients and investors on Tuesday, October 8th. Zacks Research analyst K. Das now forOctober 10, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comEsperion Therapeutics (NASDAQ:ESPR) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comEsperion shares reiterate Buy rating on trial dataOctober 5, 2024 | uk.investing.comZacks Research Weighs in on Esperion Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, October 1st. Zacks Research analyst K. Das now expects that the biopharmaceuOctober 4, 2024 | marketbeat.comIs Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?October 3, 2024 | msn.comMarshall Wace LLP Buys 2,087,635 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Marshall Wace LLP increased its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 94.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,303,596 shares of the biopharmaceuticSeptember 30, 2024 | marketbeat.comEsperion Therapeutics, Inc.: Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)September 27, 2024 | finanznachrichten.deEsperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.comStockNews.com lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday.September 27, 2024 | marketbeat.comEsperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)September 25, 2024 | globenewswire.comGreat Point Partners LLC Sells 2,208,406 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Great Point Partners LLC cut its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 27.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,791,594 shares of the biopharmaceutical companySeptember 24, 2024 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Raised by XTX Topco LtdXTX Topco Ltd grew its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 751.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 364,681 shares of the biopharmaceutical cSeptember 23, 2024 | marketbeat.comInspire Investing LLC Makes New Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Inspire Investing LLC purchased a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 341,223 shares of the biopharmaceutiSeptember 21, 2024 | marketbeat.comBank of New York Mellon Corp Has $1.27 Million Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Bank of New York Mellon Corp boosted its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 3,278.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 572,323 shaSeptember 20, 2024 | marketbeat.comEsperion to Participate in Upcoming 2024 Cantor Global Healthcare ConferenceSeptember 5, 2024 | finance.yahoo.comEsperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)September 3, 2024 | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Up 9.4% in AugustEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 41,730,000 shares, a growth of 9.4% from the July 31st total of 38,140,000 shares. Based on an average daily trading volume, of 7,010,000 shares, the days-to-cover ratio is presently 6.0 days. Approximately 21.5% of the company's stock are sold short.September 1, 2024 | marketbeat.comEsperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment ConferenceAugust 26, 2024 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Upgraded at StockNews.comStockNews.com raised Esperion Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday.August 22, 2024 | marketbeat.comEsperion Therapeutics: Delivering On Expectations While Navigating OverhangsAugust 19, 2024 | seekingalpha.comEsperion Therapeutics: Strategically Positioned To GrowAugust 16, 2024 | seekingalpha.comEsperion Therapeutics, Inc. (0ET.F)August 15, 2024 | uk.finance.yahoo.comEsperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comBuy Rating Affirmed for Esperion on Robust Revenue Growth and Enhanced Market AccessAugust 13, 2024 | markets.businessinsider.comQ2 2024 Esperion Therapeutics Inc Earnings CallAugust 13, 2024 | finance.yahoo.comBiggest stock movers today: ESPR and HUMAAugust 13, 2024 | msn.com Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.360.45▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼74▲ESPR Articles Average Week Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Radius Recycling News Today Omeros News Today Cara Therapeutics News Today Centessa Pharmaceuticals News Today Harmony Biosciences News Today Evotec News Today Recursion Pharmaceuticals News Today Tarsus Pharmaceuticals News Today Disc Medicine News Today Galapagos News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
